Dysmenorrhea is a disease caused by an overproduction of cytokines and prostaglandins throughout the menstrual cycle. NSAIDs are commonly used to relieve pain, but they can cause nausea, vomiting, hormonal imbalance, infertility, and irregularities in the menstrual cycle if used for a longer interval. Menthol, Cinnamaldehyde, Quercetin, and trans-anethole are combined in a novel Topical formulation that has significant anti-inflammatory and anti-dysmenorrheal activities with fewer side effects, and the excipients added improve the permeability rate and pharmacological action. The formulation quickly penetrates the stratum corneum and operates on the uterus’ endometrial lining cells, blocking pro-inflammatory cytokines including LPS, TNF, IL1, IL6, COX-2, LOX, oxidative stress, and lowering antioxidant levels. Menthol in the formulation has cooling and anti-spasmodic properties, making it effective in the treatment of dysmenorrhea-related nausea, vomiting, and diarrhoea. Anethol regulates excessive contractions via modifying Ca2+ and K+ channels. Cinnamaldehyde and Quercetin decrease inflammation by inhibiting the release of key cytokines and pro-inflammatory mediators. The yield value, sensory testing, spreadibility, dynamic viscosity, pH, anti-microbial preservative concentration, microbiological limit, sterlity testing, skin permeation test, and assay testing will all be used to evaluate the formulation. The O/W cream that has been developed will be far more effective than conventional NSAIDs, will be simple to apply, and will not disturb the menstrual cycle.